Exploring the inherent susceptibility of cancer-associated fibroblasts to oncolytic virus infection

Authors:

Abstract
Oncolytic virus (OV) therapy represents a promising approach currently undergoing (pre)-clinical testing for several cancers. Until recently, it was thought that the tropism of oncolytic viruses was restricted to epithelial cancer cells unless they were modified to target additional cell types. It has now become evident that some OVs possess a natural ability to target cancer-associated fibroblasts (CAFs). CAFs are strongly highlighted in supporting cancer progression and impeding anti-cancer therapeutics. Therefore, targeting CAFs in addition to tumor cells could enhance therapy efficacy. To date, the molecular determinants of tumor cell permissiveness to OV therapy have been thoroughly investigated. The recent notion that CAFs could also be a target for OVs highlights the importance of a comparable understanding of what makes CAFs permissive to OVs. This review explores the various molecular pathways and molecules that may affect the susceptibility of CAFs to OV infection and lysis. We discuss the potential impact of virus entry receptors, microRNAs, Ras and PI3K/AKT signaling, p53 status and type I interferon signaling. Further scrutinizing the factors that influence sensitivity of CAFs to OVs can help to identify targets for therapy optimization, especially in tumors with a high abundance of CAFs.
Funding Information
  • Overleven met Alvleesklierkanker (SOAK 21.02)
  • Dutch Research Council

This publication has 149 references indexed in Scilit: